XOMA sells royalty rights on Cimzia for $4 million
California, USA-based therapeutic antibody firm XOMA (Nasdaq: XOMA) says it has sold its royalty interest in Cimzia (certolizumab pegol), which is marketed by Belgian drugmaker UCB (BB; UCB), for $4 million to an undisclosed buyer.
The manufacture of Cimzia is covered by a license to XOMA's Bacterial Cell Expression technology. The licensed US patents will expire in 2014. Cimzia is a pegylated antibody fragment that targets tumor necrosis factor alpha. It is approved in the US to treat Crohn's disease and rheumatoid arthritis. In the first six months of this year Cimzia, which has only recently been launched, generated sales of 83 million euros ($105.9 million), up 240%, for UCB.
Cimzia is UCB's most important new product. Based on a consensus sales forecast of $821 million by 2014, the drug is worth $2.26 billion to the firm, according to EvaluatePharma's NPV Analyzer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze